Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

News

News
02/01/2021
Journal of Clinical Pathways
News
01/28/2021
Study findings suggest pembrolizumab is not a cost-effective second-line therapy for HCC at its current price in the US.
Study findings suggest pembrolizumab is not a cost-effective second-line therapy for HCC at its current price in the US.
Study findings suggest...
01/28/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement